Considerations When Using Gabapentinoids to Treat Trigeminal Neuralgia: A Review.

Abstract

Despite the exemplary efficacy of voltage-gated sodium channel blockers as a first-line treatment of trigeminal neuralgia, the pharmacological management of this excruciating facial pain condition remains a major issue, as these first-line drugs produce intolerable side effects in a significant portion of patients. In addition, in patients with concomitant continuous pain, the efficacy of these drugs may drop, thus suggesting the opportunity to test the efficacy of different drug categories. The aim of this review is to provide current, evidence-based, knowledge about the use of gabapentin and other α2δ ligands in patients with trigeminal neuralgia. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews and the Clinical Trials database (ClinicalTrials.gov), considering publications up to April 2023. Two authors independently selected studies for inclusion and data extraction. The efficacy of α2δ ligands, gabapentin and pregabalin, has been assessed in seven controlled or open-label studies. Despite the low quality of evidence, the favorable tolerability profile and the possible action on concomitant continuous pain make this drug category of interest for future trials in trigeminal neuralgia.

• Authors: Gianfranco De Stefano, Giuseppe Di Pietro, Andrea Truini, Giorgio Cruccu, Giulia Di Stefano
• Journal: Neuropsychiatric disease and treatment (Neuropsychiatr Dis Treat) Vol. 19 Pg. 2007-2012 ( 2023) ISSN: 1176-6328 [Print] New Zealand
• PMID: 37745191 (Publication Type: Journal Article, Review)
• Copyright: © 2023 De Stefano et al.